InvestorsHub Logo
Followers 26
Posts 8986
Boards Moderated 0
Alias Born 12/11/2013

Re: Rdunn88 post# 365107

Monday, 07/12/2021 5:35:04 PM

Monday, July 12, 2021 5:35:04 PM

Post# of 402943
Here's what's in store for IPIX if they miss... At least with the Prurisol hype they had yearly meetings, other ongoing projects, quarterly updates and shared financing news/strategy... The past 16 months Leo deserted all past practices to promote B for C so one-sided... The PR history is bloated with total deception...

https://www.prnewswire.com/news-releases/shareholder-alert-cytodyn-inc-cydy-officers-and-directors-under-investigation-for-possible-false-statements-and-insider-trading-301309852.html

In or around March 2020, in the early stages of the COVID-19 pandemic, CytoDyn attempted to pivot its existing drug candidate, leronlimab, which was originally developed for the treatment of HIV, to be used instead as a treatment for severe cases of COVID-19. According to two securities class action lawsuits on file in the U.S. District Court for the Western District of Washington, plaintiffs allege that CytoDyn touted leronlimab for this purpose through March 9, 2021 by, among other things, selectively disclosing the progress of clinical trials and the drug's purported efficacy in certain narrow population subgroups. However, on May 17, 2021, the U.S. Food and Drug Administration advised that, contrary to CytoDyn's public statements, "it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19." The FDA further advised that even in the narrow subgroups identified by CytoDyn, "[n]one of these analyses met statistical significance when using established and reliable analytical methods." During the same period when CytoDyn was touting the drug as a potential COVID-19 treatment, three high-level CytoDyn insiders sold more than $29.9 million of company stock at prices inflated by the alleged false and misleading statements.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News